Clinical trial news

Moonfish SMA trial on hold

International pharmaceutical company Roche, with its SMA drug development collaboration partners PTC Therapeutics and the SMA Foundation, said a clinical study called Moonfish (NCT02240355) that was investigating a compound and investigational medicine known as RG7800 for people with spinal muscular atrophy (SMA) was placed on clinical hold in April 2015 after…

Olesoxime for spinal muscular atrophy

Olesoxime (TRO19622) is an experimental neuroprotective compound, initially developed by Trophos, for patients with spinal muscular atrophy (SMA). In early 2015, Roche acquired Trophos, along with the therapy. However, as of June 2018, Roche announced it was halting the development of olesoxime for SMA due to disappointing…

sma therapy tracker

Click on a therapy to read the latest news: At present, there are no FDA approved therapies for Spinal Muscular Atrophy (SMA), and often times it is difficult to find information about new scientific and research advancements. A lack of information can lead to a feeling of hopelessness among…

Progress reports on six treatment options for spinal muscular atrophy (SMA), all currently in clinical trials, were recently spotlighted at the 2016 Annual SMA Conference in Anaheim, Calif. In this Nationwide Children’s Hospital video meet the Kingsley family and 6-year-old Brett who was diagnosed…